Defective Self-Renewal and Differentiation of GBA-Deficient Neural Stem Cells Can Be Restored By Macrophage Colony-Stimulating Factor

Hyun Lee1, Jae-sung Bae2,4,*, and Hee Kyung Jin1,2,*

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the glucocerebrosidase gene (GBA), which encodes the lysosomal enzyme glucosylceramidase (GCase). Deficiency in GCase leads to characteristic visceral pathology and lethal neurological manifestations in some patients. Investigations into neurogenesis have suggested that neurodegenerative disorders, such as GD, could be overcome or at least ameliorated by the generation of new neurons. Bone marrow-derived mesenchymal stem cells (BM-MSCs) are potential candidates for use in the treatment of neurodegenerative disorders because of their ability to promote neurogenesis. Our objective was to examine the mechanism of neurogenesis by BM-MSCs in GD. We found that neural stem cells (NSCs) derived from a neuronopathic GD model exhibited decreased ability for self-renewal and neuronal differentiation. Co-culture of GBA-deficient NSCs with BM-MSCs resulted in an enhanced capacity for self-renewal, and an increased ability for differentiation into neurons or oligodendrocytes. Enhanced proliferation and neuronal differentiation of GBA-deficient NSCs was associated with elevated release of macrophage colony-stimulating factor (M-CSF) from BM-MSCs. Our findings suggest that soluble M-CSF derived from BM-MSCs can modulate GBA-deficient NSCs, resulting in their improved proliferation and neuronal differentiation.

INTRODUCTION

Gaucher disease (GD) is caused by an inherited deficiency in the enzyme glucosylceramidase (GCase). Mutations in the glucocerebrosidase gene (GBA), which encodes GCase, leads to defective hydrolysis of glucocereamide (GluCer), subsequently resulting in the storage of GluCer in the liver, spleen, bone marrow, and central nervous system (CNS) (Beutler and Grabowski, 2001; Brady et al., 1966). Clinically, two major categories of GD have been recognized: non-neuronopathic and neuronopathic. These can be further sub-divided into three types. Type 1 GD is the most common form of the disease and includes non-neuronopathic variants. Types 2 and 3 GD encompass acute and subacute neuronopathic variants (Beutler and Grabowski, 2001). In neuronopathic GD, pathogenesis in the CNS is related to neuronal death and dropout, which is propagated by the toxic effects of GluCer (Conradi et al., 1984; 1988; Sidransky et al., 2004). Little is known about the molecular events leading to neuronal death, and at present, there is no treatment available for neuronopathic GD.

In the adult brain, neurogenesis of neural stem cells (NSCs) and progenitor cells occurs in two regions: the subventricular zone of the lateral ventricles and the subgranular zone of the hippocampus (Ming and Song, 2011). The discovery of neurogenesis in the adult brain has raised the possibility of potential therapeutic applications to overcome neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease (Ming and Song, 2011). These findings indicate that neurodegenerative diseases, such as GD, are suitable targets for the therapeutic stimulation and regulation of neurogenesis.

In a previous study, we showed that bone marrow-derived mesenchymal stem cells (BM-MSCs) contributed to improving neurogenesis in a mouse model of Niemann-Pick type C (Lee et al., 2013). This therapeutic function of MSCs can, in part, be explained by their production of diffusible trophic factors (Block et al., 2009; Ren et al., 2007; Zhang et al., 2004; 2005). Deng et al. (2006) previously demonstrated elicitation of neurogenesis and promotion of functional recovery by transplanting MSCs in rhesus monkeys. Our goal in the current study was to investigate the neurogenic potential of BM-MSCs, and of soluble factors released from BM-MSCs, for the promotion of NSC neurogenesis in a neuronopathic GD model.

Treatment with BM-MSCs resulted in an enhanced capacity for self-renewal, proliferation, and neuronal differentiation of...
GBA-deficient NSCs. Our observations suggest that macrophage colony-stimulating factor (M-CSF) plays a key role as a paracrine factor for the neurogenic effects of BM-MSCs in GBA-deficient NSCs.

MATERIALS AND METHODS

Animals

Gba<sup>flox</sup>/nestin-Cre mice were used as a model of neuronopathic GD (Enquist et al., 2007). Gba<sup>flox/−</sup> mice were crossed with Gba<sup>+</sup>/nestin-Cre mouse to generate Gba<sup>flox/−;nestin-Cre</sup> mice (hereafter referred to as Gba<sup>−/−</sup> mice) and Gba<sup>+/−</sup>/nestin-Cre mice (hereafter referred to as Gba<sup>+/−</sup> mice), which served as wild-type controls. Genotyping was performed by polymerase chain reaction (PCR), using genomic DNA extracted from the tails of mice (Farfel-Becker et al., 2009). All procedures were performed in accordance with a protocol approved by the Kyungpook National University Institutional Animal Care and Use Committee. Animals were housed in a temperature-controlled room with a 12-h light-dark cycle.

Isolation and culture of NSCs

Using a previously described method (Chen et al., 2007) with some minor modifications, dissociated NSCs were prepared from the cerebral cortex of 1-day-old neonatal Gba<sup>−/−</sup> or Gba<sup>+/−</sup> mice. The cortex was removed and kept in ice-cold Ca<sup>2+</sup>/Mg<sup>2+</sup>-free Hank’s balanced salt solution (Invitrogen, USA). The cortex was then mechanically dissociated in NSC culture medium (Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Invitrogen), 1% N2 supplement (Invitrogen), 20 ng/ml epidermal growth factor (Peprotech), 20 ng/ml basic fibroblast growth factor (Peprotech)). Cell suspensions were filtered through a 40-μm cell strainer, single-cell suspensions from NSs were seeded on glass coverslips coated with poly-L-ornithine (Sigma, USA) and laminin (Invitrogen), at a density of 1.0 × 10<sup>4</sup> cells/cm<sup>2</sup>. Cells were incubated in 2 N HCl for 1 h, and then in 0.15 M sodium borate buffer (Sigma), and incubated for an additional 12 h. After the labeling medium was removed, cells were fixed with phosphate-buffered saline (PBS; Invitrogen), processed for immunofluorescence analysis of BrdU, and incubated with nuclear buffered saline (PBS; Invitrogen), processed for immunofluorescence analysis of BrdU, and incubated with the nuclear counterstain 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories Inc., USA).

NS formation assays

To examine the effects of BM-MSCs on NS formation, NSs were mechanically dissociated, and the resulting viable cells quantified. These cells (1 × 10<sup>6</sup> cells/well in uncoated 24-well plates; BD Biosciences) were also used to assess the self-renewal ability in NSC culture medium. Following co-culture with BM-MSCs or treatment with recombinant murine M-CSF (2-50 ng/ml; R&D Systems, USA), newly formed NSs were counted in each well using an IX71 microscope (Olympus Co., Japan). A minimum cutoff diameter of 50 μm was used to define NSs.

NSC proliferation assays

The proliferative activity of NSCs was evaluated by 5-bromo-2-deoxyuridine (BrDU) immunocytochemistry. Single-cell suspensions from NSs were seeded on glass coverslips coated with poly-L-ornithine (Sigma, USA) and laminin (Invitrogen), at a density of 1 × 10<sup>6</sup> cells/cm<sup>2</sup>. Cells were incubated with BM-MSCs or M-CSF for 7 days, labeled with a 10 μM of BrDu (Sigma), and incubated for an additional 12 h. After the labeling medium was removed, cells were fixed with phosphate-buffered 4% (w/v) paraformaldehyde (Sigma) for 20 min at room temperature (RT). To denature nuclear DNA, cells were incubated in 2 N HCl for 1 h, and then in 0.15 M sodium borate for 15 min (all from Sigma). Cells were washed with phosphate-buffered saline (PBS; Invitrogen), processed for immunofluorescence analysis of BrdU, and incubated with the nuclear counterstain 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories Inc., USA).

Lipid extraction and GluCer quantitation

We prepared samples for lipid extraction as previously described (He et al., 2010). To quantify GluCer levels, human recombinant acid ceramidase (rhAC) and GCase (Cerezyme, Genzyme Corporation, USA) were added to the lipid extracts, and GluCer was fully hydrolyzed to sphingosine. The amount of sphingosine was then quantified using the procedure described by He et al. (2005). Briefly, 2 μl of lipid extract in 0.2% Igepal CA-630 was mixed with 2 μl of a GluCer hydrolysis buffer (0.2 M citrate-phosphate buffer, pH 4.5, 0.3 M NaCl, 50 ng/ml rhAC, 2.5% GCase) and incubated at 37°C for 1 h. Reactions were stopped by adding 20 μl of NDA derivatization reaction mixture (25 mM borate buffer, pH 9.0, 2.5 mM NDA, 2.5 mM sodium cyanide). The reaction mixture was diluted 1:3 with ethanol, incubated at 50°C for 10 min, and then centrifuged (13,000 × g for 5 min). An aliquot (30 μl) of the supernatant was then transferred to a glass sample vial and 5 μl was added onto an UPLC system for analysis. Fluorescent sphingosinederivatives were monitored using a model 474 scanning fluorescence detector (Waters). Quantitation of the sphingosine peak was calculated from sphingosine standard calibration curves, using the Waters Millennium software. To calculate the final GluCer content of samples, background of endogenous sphingosine and ceramide signals, determined as above, using a reaction mixture lacking GCase, were subtracted from the signal obtained in the presence of rhAC and GCase.

Defective of GBA-Deficient NSC Can Be Restored By M-CSF

Hyun Lee et al.
NSC differentiation assays
For NSC differentiation assays, single-cell suspensions cultured in vitro for 7 days were plated on glass coverslips coated with poly-L-ornithine and laminin at a density of 1 × 10^4 cells/cm². Coverslips were incubated in Neurobasal-A medium supplemented with 100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 10 μg/ml of heparin, 2% B-27 supplement, and 3% fetal bovine serum (FBS; all from Invitrogen). Differentiated cultures were processed for immunofluorescence staining at 7 days post-plating.

Immunocytochemistry
Cells were fixed with 0.1 M PBS containing 4% paraformaldehyde at RT for 15 min, and then permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 5 min. Cells were preincubated for 10 min with 3% normal goat serum (Vector Laboratories Inc.) and 2% bovine serum albumin (BSA; Invitrogen) in PBS containing 0.4% Triton X-100 to block background signals. For the NSC differentiation assays, differentiated cultures were incubated with various primary antibodies overnight at 4°C. We used a mouse monoclonal antibody against βIII-tubulin (diluted 1:400; Chemicon, USA) as a marker for neurons, a rabbit polyclonal antibody against GFAP (diluted 1:1,000; Dako, Denmark) as a marker for astrocytes, or a rabbit polyclonal antibody against MBP (diluted 1:500; Abcam, UK) as a marker for oligodendrocytes. For visualization of primary antibodies, appropriate Alexa Fluor 488-conjugated secondary antibodies (diluted 1:1,000; Molecular Probes, USA) were added to cultures and allowed to incubate for 1 h at RT. Immunofluorescence in cells was analyzed using a laser-scanning confocal microscope equipped with Fluoview SV1000 imaging software (Olympus FV1000, Olympus Co., Japan), or with a BX51 microscope (Olympus Co.).

Neurite outgrowth assay
Morphological analysis of differentiated neurons was recorded using the MetaMorph software (Universal Imaging Corp., USA). All recordings and MetaMorph analysis were performed in a blinded manner.

Antibody-based mouse cytokine arrays
RayBio Mouse custom Cytokine Antibody Arrays (Raybiotech, USA) were used to assay cell culture supernatants from coculture experiments, according to the manufacturer’s instructions. Membranes were incubated with 2 ml of blocking buffer at RT for 30 min. About 1 ml of the conditioned medium from samples with or without co-cultured BM-MSCs was then added, followed by incubation overnight at 4°C. After decanting samples, membranes were washed with wash buffers I and II at RT with shaking at 120 rpm. Membranes were then incubated with 1 ml of biotin-conjugated antibodies (1:250) overnight at 4°C and washed, followed by incubation with 2 ml of horseradish peroxidase-conjugated streptavidin (1:1000) for 1 h at RT, and further washing. Detection buffers C and D were used for visualization of spots. Membranes were wrapped in plastic wrap, exposed to Kodak X-Omat radiographic film (Kodak, USA) for 20 min, and signals were detected using a film developer. Each film was scanned into an image processor, and densitometric measurements were performed using an imaging densitometer (Bio-Rad, USA), followed by quantitation with Bio-Rad analysis software. Densitometry and statistical analyses were performed on the immunoblots, with normalization to the positive and negative controls on the array.

Reverse-transcription PCR (RT-PCR) and quantitative PCR (qPCR) assays
The RNeasy Plus Mini Kit (Qiagen, Germany) was used to extract RNA from cell lysates. We synthesized complementary DNA (cDNA) from 5 μg of total RNA, using a cDNA Synthesis Kit (Clontech, USA), according to the manufacturer’s instructions. Reactions were incubated at 42°C for 1 h, and then at 70°C for 10 min to arrest cDNA synthesis. We performed qPCR assays using a Corbett research RG-6000 thermal cycler (Corbett Life Science, Australia). The thermal cycling profile involved 40 amplification cycles (95°C for 10 s, 58°C for 15 s, 72°C for 20 s). We used oligonucleotide primers that were specific for Mcsf (5′-AGT CTC TCT TCC ACC TGC TG-3′ and 5′-TTC CAC TCT TCT CTC AT-3′), IL-1ra (5′-GCA GCA CAG GCT GGT GAA TGA C-3′ and 5′-TCC CCC GGT GGA CCA AG-3′), MCP-1 (5′-ATG CAG TTA ATG CCC CAC TC-3′ and 5′-TTT CTT ATT GGG GTC AGC AC-3′), Mmp2 (5′-CCC CGA TGC TGA TAC TGA-3′ and 5′-CTG TCG TCC GCC AAA TAA ACC-3′), Mmp3 (5′-TAG AAG GAG GCA GCA GAG AA-3′ and 5′-GAA TAG GAT GAG AAC ACA AC-3′) and GAPDH (5′-AAC AGC CTC AAG ATC ATC AGC-3′ and 5′-TTG GCA GGT TTT TCT AGA CGG-3′).

Enzyme-linked immunosorbent assay (ELISA) determination of M-CSF concentrations
We used a Quantikine Mouse M-CSF ELISA Kit (R&D Systems) and approved M-CSF standards to measure the concentration of M-CSF, according to the manufacturer’s instructions. Each standard and experimental sample was assayed in duplicate, and the results were averaged.

Statistical analysis
Comparisons between two groups were conducted with Student’s t-test. Tukey’s HSD test and repeated measures analysis of variance test (ANOVA) were used for multigroup comparisons, with the aid of SPSS statistical software. Differences were accepted to be statistically significant at p < 0.05.

RESULTS
Deletion of Gba results in severe GCase deficiency and substrate accumulation of GluCer in NSCs
To confirm that nestin-Cre-mediated deletion of the GCase gene disrupted GCase activity, NSCs were obtained from Gba<sup>−/−</sup> and Gba<sup>+</sup> mice. NSCs isolated from the cortex of Gba<sup>−/−</sup> neonatal mouse exhibited reduced GCase activity (Fig. 1A), and higher levels of GluCer compared with that in control NSCs (Fig. 1B).

BM-MSCs enhance the self-renewal and proliferation of Gba<sup>−/−</sup> NSCs
To examine the neurogenic potential of BM-MSCs, we used self-renewal and proliferation assays (Fig. 2A). The number of NSs in Gba<sup>−/−</sup> cultures was significantly lower compared with that in Gba<sup>−/−</sup> cultures (Fig. 2B). In addition, indirect co-culture of Gba<sup>−/−</sup> NSCs with BM-MSCs resulted in the increased formation of NSs (Fig. 2B). BM-MSCs also induced an increase in NS formation in Gba<sup>−/−</sup> cultures. To assess proliferation, adherent NSCs were pulsed with BrdU and the proportion of labeled cells of NSs (Fig. 2B). BM-MSCs also induced an increase in NS formation in Gba<sup>−/−</sup> cultures.
Deletion of Gba results in a severe enzyme deficiency and accumulation of GluCer in the NSCs. (A) GCase activity was reduced to a greater degree in NSCs of Gba−/− mice compared with that in NSCs of Gba+/− mice (n = 5 per group). (B) GluCer accumulated in NSCs from Gba−/− mice (n = 5 per group). All data are presented as the mean ± SEM. *p < 0.05 compared with the Gba+ controls.

| Gba−/− | Gba+ | Gba−/− | Gba+ |
|--------|------|--------|------|
| 500    | 100  | 300    | 50   |

**BM-MSCs affect differentiation of NSCs into specific cell types**

In addition to their ability for self-renewal, the second hallmark of stemness in NSCs is multilineage differentiation (Reynolds and Weiss, 1996). We dissociated NSs and co-cultured cells with BM-MSCs in differentiation media. Immunocytochemistry was performed to investigate the effects of BM-MSCs on Gba−/− NSC cultures and their capacity for differentiation into the three main neural lineages (Fig. 3A). Expression of three neural lineage markers (βIII-tubulin, MBP, and GFAP) were detected in NSC-derived cells regardless of whether they were co-cultured with BM-MSCs (Figs. 3B-3E). In comparison with Gba−/− cells, the efficiency of neuronal differentiation was not significantly different. We observed significantly reduced neurite outgrowth and number of processes in differentiated neurons from Gba−/− NSC cultures (Figs. 3B and 3C). Indirect co-culture of Gba−/− NSCs with BM-MSCs resulted in significantly enhanced efficiency of neuronal differentiation, increased neurite outgrowth, and an increased number of processes (Fig. 3C). Compared with Gba−/− NSCs, we observed a reduced rate of differentiation for MBP-expressing cells in Gba+ NSC cultures (Fig. 3D). Co-culture with BM-MSCs resulted in a significant increase in the number of differentiating oligodendrocytes in Gba−/− NSC cultures (Fig. 3D). Compared with Gba−/− cells however, there were no significant changes in the numbers of GFAP-positive cells in differentiated Gba−/− NSC cultures (Fig. 3E).

**BM-MSCs increase neurotrophic factor signaling**

Our observations indicate that soluble bioactive factors secreted from BM-MSCs could promote the proliferation of Gba−/− NSCs. To identify these factors, we screened and compared the conditioned media of the various Gba−/− and Gba+ NSC cultures for 50 different secreted cytokines, using an antibody-based mouse cytokine array (Fig. 4A). Expression levels of M-CSF, IL-1ra, MCP-1, Mmp-2 and Mmp-3 were greater in the conditioned media of Gba−/− NSCs co-cultured with BM-MSCs than in the conditioned media of NSCs without co-culture (Fig. 4A). These results suggest the involvement of M-CSF, IL-1ra, MCP-1, Mmp-2, and Mmp-3 with respect to the self-renewal of Gba−/− NSCs co-cultured with BM-MSCs. Using qPCR assays, we examined mRNA expression levels of Mcsf, IL-1ra, MCP-1, Mmp2, and Mmp3 in Gba−/− and Gba+ NSCs. Compared with controls, expression of Mcsf was significantly decreased in Gba−/− NSCs (Fig. 4B). Levels of IL-1ra, MCP-1, Mmp2, and Mmp3 were increased in Gba−/− NSCs compared with those in Gba+ NSCs. We suspect that reduced expression of M-CSF might lead to the impaired self-renewal observed in Gba−/− NSCs. M-CSF derived from BM-MSCs is a potential candidate molecule for alleviating this defect. To confirm the secretion of this factor, we performed ELISAs and found that M-CSF levels were significantly elevated in the conditioned media of Gba−/− NSCs co-cultured with BM-MSCs (Fig. 4C). We also found that M-CSF levels were significantly decreased in Gba−/− NSCs compared with those in Gba+ NSCs (Fig. 4C), neither of which were co-cultured with BM-MSCs.

**BM-MSCs enhance the self-renewal and proliferation of Gba−/− NSCs.**

(A) Experimental design to determine the effects of BM-MSCs on Gba−/− NSCs. (B) Light micrographs of NSs following BM-MSC co-culture with Gba−/− NSCs (scale bar, 1 mm). Self-renewal capacity is expressed as the number of NSs (n = 6 per group). (C) Effect of BM-MSCs on the Gba−/− NSCs (scale bar, 20 μm). Proliferation ability was assessed by the percentage of BrdU-positive cells (n = 7 per group). (D) Effect of BM-MSCs on the GCase activity of Gba−/− NSCs (n = 3 per group). All data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005.
Defective of GBA-Deficient NSC Can Be Restored By M-CSF
Hyun Lee et al.

**M-CSF enhances the self-renewal, proliferation, and neuronal differentiation of Gba⁻/⁻ NSCs**

To examine the neurogenic potential of M-CSF, we evaluated the effects of recombinant murine M-CSF on the self-renewal of NSCs at different concentrations. M-CSF increased the number of NSs in Gba⁻ cultures at 10 and 50 ng/ml (Fig. 5A). Therefore, we used 10 ng/ml M-CSF for subsequent experiments. Compared with Gba⁺ NSs, the self-renewal ability of Gba⁻ NSs was significantly decreased. The Gba⁺ NSs treated with M-CSF exhibited increased formation of NSs (Fig. 5A). To assess proliferation, the percentage of BrdU-labeled cells was determined. M-CSF increased BrdU incorporation in Gba⁻ cultures relative to that in untreated Gba⁻ cultures (Fig. 5B). In addition to examining the effects of M-CSF on neuronal differentiation, NSs were dissociated and treated with M-CSF in differentiation media. After 7 days, the expression of neuronal markers was evaluated in NSC-derived cells. Compared with Gba⁺ cells, Gba⁻ neurons showed significantly decreased neuronal outgrowth and a reduced number of processes (Fig. 5C). M-CSF treatment of Gba⁻ NSCs resulted in increased efficiency of neuronal differentiation, along with an increase in the number of processes and enhanced neuronal outgrowth (Fig. 5C). Taken together, our findings suggest that M-CSF increases self-renewal, proliferation, neuronal differentiation and neuronal morphogenesis of Gba⁻ NSCs.

**DISCUSSION**

The present study is a part of a search for novel therapeutic strategies to treat neuronopathic GD, which are based on the concept of neuronal regeneration. Neuropathologically, human and murine GD is characterized by neuronal loss, neurophagia, and demyelination (Adachi et al., 1967; Farfel-Becker et al., 2011; Kaga et al., 1982; 1998). These histological changes result in the clinical features observed in patients, including hypertonia of the neck, seizures, and ataxia (Tayebi et al., 1998; Tylki-Szymańska et al., 2010). The principal goal of neuronopathic GD therapy is to restore function to malfunctioning cells, particularly neurons. We observed that the ratio of neuronal differentiation was not significantly different between Gba⁻/⁻ and Gba⁺ NSCs. However, terminally differentiated neurons from Gba⁻ NSCs showed reduced neurite outgrowth and number of processes. Therefore, stimulating neurogenesis is appropriate for the treatment of patients with GD.

Several neurogenic activities associated with BM-MSCs have been investigated (Deng et al., 2006; Zhang et al., 2004). Our findings presented here correspond with those from previous investigations regarding the stimulatory effects of BM-MSCs on neurogenesis (Croft and Przyborski, 2009; Lee et al., 2013; Yoo et al., 2008). *In vitro* observations demonstrated that indirect co-culture with BM-MSCs could result in the alleviation of defects associated with the self-renewal and proliferation of Gba⁻ NSCs. We also observed that their differentiation into neurons or oligodendrocytes was enhanced. These findings suggest that the effects of BM-MSCs on self-renewal, proliferation and differentiation can be attributed to the indirect effects of soluble factors secreted from BM-MSCs and that these cells selectively promote neurogenesis and oligogenesis from NSCs. The neurogenic effect of BM-MSCs is mediated by a variety of soluble factors (Croft and Przyborski, 2009). Although the differentiation potential of BM-MSCs for tissue repair has been demonstrated numerous times, a repeated finding from several experiments
Defective of GBA-Deficient NSC Can Be Restored By M-CSF

Hyun Lee et al.

Fig. 4. BM-MSCs increased neurotrophic factor signaling. (A) A cytokine antibody array was incubated with conditioned media recovered from three-dimensional cultures of BM-MSC-treated NSCs or untreated NSCs. Co-culture of Gba⁺ NSCs with BM-MSCs resulted in the upregulation of M-CSF, IL-1ra, MCP-1, MMP-2, and MMP-3 (red squared spots). Densitometry analyses of cytokine/chemokine signals were normalized to positive and negative antibody array controls for Gba⁺/⁻ NSCs. (B) Analysis using qPCR assays revealed greater transcriptional down-regulation of M-CSF in NSCs from Gba⁻ mice compared with that in Gba⁺ mice (n = 4 per group). *p < 0.05 compared with the Gba⁺ controls. (C) ELISA analysis was used to assess M-CSF expression in NSCs. M-CSF expression was reduced to a greater extent in NSCs of Gba⁻ mice compared with that in Gba⁺ NSCs. Gba⁻ NSCs co-cultured with BM-MSCs exhibited greater M-CSF expression levels compared with those in Gba⁺ NSCs that were not co-cultured with BM-MSCs (n = 5 mice per group). All data are presented as the mean ± SEM. *p < 0.05.

was that these cells frequently confer functional improvements without significant evidence of either engraftment or differentiation (Parr et al., 2007; Prockop, 2007). Results from these studies suggest that the repair of tissues by BM-MSCs does not occur solely as a result of their stem cell-like ability to differentiate, but could also be attributed to the release of growth factors and other molecules that might elicit therapeutic effects (Prockop et al., 2003). To determine the paracrine factors that mediate MSC effects on the proliferation of Gba⁺ NSCs, we used cytokine arrays for analysis of media samples from co-cultures. Our results revealed increased expression of M-CSF in the conditioned media of BM-MSC co-cultures. We also observed that the effects of BM-MSCs on proliferation and differentiation were increased for Gba⁺ NSC cultures treated with M-CSF. Previous research has shown that, independent of neuropathology, chemokines and their receptors are expressed in the developing brain, and play roles in orienting cell migration, trophic support, proliferation, and/or differentiation (Bajetto et al., 2001). The M-CSF receptor (CSF-1R) is expressed in neural progenitors and plays a direct role in the regulation of progenitor cell proliferation and differentiation (Nandi et al., 2012). The direct regulation of neural progenitors through CSF-1R is biologically significant as demonstrated by the perinatal lethality of Csf1r⁻/⁻;nestin-Cre mice, which phenocopies the perinatal death of Csf1r⁻/⁻ mice (Nandi et al., 2012). These results suggest that M-CSF is an effective adjuvant for improving neurogenic effects, and that M-CSF derived from BM-MSCs could be a critical factor for increasing the proliferation and neural differentiation of Gba⁻ NSCs.

In conclusion, our data suggest that BM-MSCs can improve the developmental deficits of Gba⁻ NSCs by augmenting proliferation, differentiation, and neuronal morphogenesis. We have
Defective of GBA-Deficient NSC Can Be Restored By M-CSF
Hyun Lee et al.

Fig. 5. M-CSF enhances the self-renewal, proliferation, and neuronal differentiation of Gba⁻/⁻ NSCs. (A) Gba⁻/⁻ NSCs were treated with different concentrations of recombinant murine M-CSF (2-50 ng/ml), and self-renewal was assessed. M-CSF at concentrations of 10 and 50 ng/ml increased the number of Gba⁻/⁻ NSCs (n = 3 per group). (B) M-CSF affects the proliferation of Gba⁻/⁻ NSCs (scale bar, 20 μm). Proliferation ability was assessed by the percentage of BrdU-positive cells (n = 3 per group). (C) Representative fluorescence images and quantitation of βIII-tubulin (scale bar, 50 μm; n = 3 per group). All data are presented as the mean ± SEM. §p < 0.05, §§§p < 0.005 compared with Gba⁺/+ controls. #p < 0.05 compared with non-treated controls. *p < 0.05, ***p < 0.005.

provided evidence that BM-MSCs can act as key mediators of neurogenesis, which could in turn have implications for the management of GD.

ACKNOWLEDGMENTS
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI12C0313).

REFERENCES
Adachi, M., Wallace, B.J., Schneck, L., and Volk, B.W. (1967). Fine structure of central nervous system in early infantile Gaucher's disease. Arch. Pathol. 83, 513-526.
Bae, J.S., Han, H.S., Youn, D.H., Carter, J.E., Modo, M., Schuchman, E.H., and Jin, H.K. (2007). Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration. Stem Cells 25, 1307-1316.
Bajetto, A., Bonavia, R., Barbero, S., Florio, T., and Schettini, G. (2001). Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 22, 147-184.
Beutler, E., and Grabowski, G.A. (2001). Glucosylceramide lipidosis-Gaucher disease. In: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, eds. The metabolic and molecular bases of inherited diseases. 8th ed. (New York, USA: McGraw-Hill), pp. 3635-3668.
Block, G.J., Ohkouchi, S., Fung, F., Frenkel, J., Gregory, C., Pochampally, R., DiMattia, G., Sullivan, D.E., and Prockop, D.J. (2009). Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 27, 670-681.
Brady, R.O., Kanfer, J.N., Bradley, R.M., and Shapiro, D. (1966). Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45, 1112-1115.
Chen, Y., Balasubramaniyan, V., Peng, J., Hurlock, E.C., Tallquist, M., Li, J., and Lu, Q.R. (2007). Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat. Protoc. 2, 1044-1051.
Conradi, N.G., Sourander, P., Nilsson, O., Svennerholm, L., and Erikson, A. (1984). Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol. 65, 99-109.
Conradi, N.G., Kalimo, H., and Sourander, P. (1988). Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottian type (type III) of Gaucher disease. Acta Neuropathol. 75, 385-390.
Croft, A.P., and Przyborski, S.A. (2009). Mesenchymal stem cells
expressing neural antigens instruct a neurogenic cell fate on neural stem cells. Exp. Neurol. 216, 329-341.
Deng, Y.B., Liu, X.G., Liu, Z.G., Liu, X.L., Liu, Y., and Zhou, G.Q. (2008). Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys. Cytotherapy 8, 210-214.
Enquist, I.B., Lo Bianco, C., Ooka, A., Nilsson, E., Månsson, J.E., Ehinger, M., Richter, J., Brady, R.O., Kirik, D., Karlsson, S. (2007). Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. USA 104, 17483-17488.
Farfel-Becker, T., Vitner, E., Dekel, H., Leshem, N., Enquist, I.B., Karlsson, S., and Futerman, A.H. (2009). No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet. 18, 1482-1488.
Farfel-Becker, T., Vitner, E.B., Pressey, S.N., Eliam, R., Cooper, J.D., Futerman, A.H. (2011). Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum. Mol. Genet. 20, 1375-1386.
He, X., Dagan, A., Gatt, S., and Schuchman, E.H. (2005). Simultaneous quantitative analysis of ceramide and sphingosine in mouse blood by naphthalene-2,3-dicarboxyaldehyde derivatization after hydrolysis with ceramidase. Anal. Biochem. 340, 113-122.
He, X., Huang, Y., Li, B., Gong, C.X., and Schuchman, E.H. (2010). Dereexpression of sphingolipid metabolism in Alzheimer’s disease. Neurobiol. Aging 31, 398-408.
Kaga, M., Azuma, C., Imamura, T., Murakami, T., and Kaga, K. (1982). Auditory brainstem response (ABR) in infantile Gaucher’s disease. Neuropediatrics 13, 207-210.
Kaga, K., Ono, M., Yakumaru, K., Owada, M., and Mizutani, T. (1998). Brainstem pathology of infantile Gaucher’s disease with only wave I and II of auditory brainstem response. J. Laryngol. Otol. 112, 1069-1073.
Lee, H., Kang, J.E., Lee, J.K., Bae, J.S., and Jin, H.K. (2013). Bone-marrow-derived mesenchymal stem cells promote proliferation and neuronal differentiation of Niemann-Pick type C mouse neural stem cells by upregulation and secretion of CCL2. Hum. Gene. Ther. 24, 655-669.
Ming, GL., and Song, H. (2011). Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70, 687-702.
Motabar, O., Goldin, E., Leister, W., Liu, K., Southall, N., Huang, W., Marugan, J.J., Sidransky, E., and Zheng, W. (2012). A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Anal. Bioanal. Chem. 402, 731-739.
Nandi, S., Gokhan, S., Dai, X.M., Wei, S., Enikolopov, G., Lin, H., Mehter, M.F., and Stanley, E.R. (2012). The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 367, 100-113.
Parr, A.M., Tator, C.H., and Keating, A. (2007). Bone marrow derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant. 40, 609-619.
Prockop, D.J. (2007). “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin. Pharmacol. Ther. 82, 241-243.
Prockop, D.J., Gregory, C.A., and Spees, J.L. (2003). One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc. Natl. Acad. Sci. USA 100, 11917-11923.
Ren, G., Li, T., Lan, J.Q., Wilz, A., Simon, R.P., and Boison, D. (2007). Lentiviral RNA-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp. Neurol. 206, 26-37.
Reynolds, B.A., and Weiss, S. (1996). Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 175, 1-13.
Sidransky, E. (2004). Gaucher disease: complexity in a ‘simple’ disorder. Mol. Genet. Metab. 82, 1-13.
Tayebi, N., Reissner, K.J., Lau, E.K., Stubblefield, B.K., Klimeburgess, A.C., Martin, B.M., and Sidransky, E. (1998). Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher’s disease. Pediatr. Res. 43, 571-578.
Tylik-Szymanska, A., Vellodi, A., Ei-Beshlawy, A., Cole, J.A., and Kolodny, E. (2010). Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J. Inherit. Metab. Dis. 33, 339-346.
Yoo, S.W., Kim, S.S., Lee, S.Y., Lee, H.S., Kim, H.S., Lee, Y.D., Suh-Kim, H. (2008). Mesenchymal stem cells promote proliferation of endogenous neural stem cells and survival of newborn cells in a rat stroke model. Exp. Mol. Med. 40, 387-397.
Zhang, J., Li, Y., Chen, J., Yang, M., Katakiowski, M., Lu, M., and Chopp, M. (2004). Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells. Brain Res. 1030, 19-27.
Zhang, J., Li, Y., Chen, J., Cui, Y., Lu, M., Elias, S.B., Mitchell, J.B., Hammill, L., Vanguri, P., and Chopp, M. (2005). Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp. Neurol. 195, 16-26.